Medtronic PLC $MDT Stock Sold by South Dakota Investment Council

South Dakota Investment Council trimmed its position in Medtronic PLC (NYSE:MDT – Free Report) by 2.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 243,131 shares of the medical technology company’s stock after selling 6,215 shares during the period. South Dakota Investment Council’s holdings in Medtronic were worth $20,980,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC boosted its stake in Medtronic by 2.0% during the 3rd quarter. Rothschild Investment LLC now owns 43,494 shares of the medical technology company’s stock valued at $3,753,000 after purchasing an additional 847 shares in the last quarter. Sompo Asset Management Co. Ltd. increased its position in shares of Medtronic by 4.6% during the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 76,806 shares of the medical technology company’s stock valued at $6,628,000 after purchasing an additional 3,403 shares during the period. First Eagle Investment Management LLC increased its position in shares of Medtronic by 1.2% during the 3rd quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company’s stock valued at $1,203,608,000 after purchasing an additional 164,425 shares during the period. Bridges Investment Management Inc. increased its position in shares of Medtronic by 25.9% during the 3rd quarter. Bridges Investment Management Inc. now owns 22,893 shares of the medical technology company’s stock valued at $1,975,000 after purchasing an additional 4,703 shares during the period. Finally, Edgestream Partners L.P. bought a new stake in shares of Medtronic in the 3rd quarter worth $8,537,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Medtronic

Here are a few of the latest headlines about MDT:

  • Positive Sentiment: The FDA cleared Medtronic’s Hugo robotic-assisted surgery system for general surgery in the U.S. The expanded authorization opens access to an estimated 3.5 million annual U.S. cases and procedures that represent more than half of U.S. soft-tissue surgeries, increasing Hugo’s commercial opportunity. Article: Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
  • Positive Sentiment: Medtronic plans to acquire Contego Medical for $380 million, adding carotid and peripheral vascular technologies to its portfolio. The deal builds on an existing U.S. distribution relationship and could strengthen its vascular-intervention business. Article: Medtronic to buy Contego Medical for $380M
  • Neutral Sentiment: A preview of Medtronic’s Q2 results points to Cardiovascular momentum, particularly cardiac ablation, with Neuroscience and Diabetes also expected to contribute growth. These are expectations ahead of the earnings report, not reported results. Article: MDT Q2 Earnings Preview

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Weiss Ratings upgraded Medtronic from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, October 19th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research note on Wednesday, September 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a report on Thursday, September 17th. Bank of America boosted their price target on shares of Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 2nd. Finally, TD Cowen set a $110.00 price target on shares of Medtronic and gave the stock a “buy” rating in a research report on Tuesday. Nineteen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.28.

Read Our Latest Analysis on Medtronic

Insider Transactions at Medtronic

In related news, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. The trade was a 8.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of Medtronic stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 in the last three months. 0.27% of the stock is currently owned by corporate insiders.

Medtronic Trading Down 0.6%

Shares of NYSE:MDT opened at $102.24 on Wednesday. The stock has a market capitalization of $130.78 billion, a price-to-earnings ratio of 25.18, a PEG ratio of 2.41 and a beta of 0.56. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. The company has a 50 day moving average price of $94.09 and a 200 day moving average price of $88.49.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 2.8%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Further Reading

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.